<scp>ModraDoc006</scp>, an oral docetaxel formulation in combination with ritonavir (<scp>ModraDoc006</scp>/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study

Abstract

The RP2D was established at weekly ModraDoc006/r 30-20/200-100. Observed PSA and radiological responses suggest promising clinical activity. These results have led to an ongoing randomized Phase 2b study, comparing weekly ModraDoc006/r with 3-weekly IV docetaxel in patients with mCRPC.